Martin Lehr
CEO
Context Therapeutics
Context Therapeutics is developing T cell engaging bispecific antibody therapies targeting solid tumors, utilizing specific mechanisms such as Claudin 6, Mesothelin, and Nectin-4 to enhance T cell activation against cancer cells. Their approach aims to improve treatment efficacy for patients with difficult-to-treat solid tumors, addressing the limitations of current therapies.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$100MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current treatments for solid tumors often have limited efficacy, leaving many patients with difficult-to-treat cancers and unmet medical needs. Existing therapies may not effectively target cancer cells or activate the immune system to fight the tumor.
Solution
Context Therapeutics is developing a pipeline of T cell engaging (TCE) bispecific antibody therapies designed to improve treatment outcomes for patients with solid tumors. Their approach involves creating bispecific antibodies that simultaneously bind to a specific tumor-associated antigen and CD3 on T cells, thereby enhancing T cell activation and directing the immune system to target and destroy cancer cells. By focusing on specific mechanisms such as Claudin 6 (CLDN6), Mesothelin (MSLN), and Nectin-4, Context Therapeutics aims to improve the precision and effectiveness of cancer immunotherapy. Their product candidates are designed to address the limitations of current therapies and offer new treatment options for patients with solid tumors.
Target Audience
The primary target audience includes patients with solid tumors who have limited treatment options, as well as oncologists and medical professionals seeking more effective therapies for these cancers.
Features
- CTIM-76: Claudin 6 (CLDN6) x CD3 bispecific antibody
- CT-95: Mesothelin (MSLN) x CD3 bispecific antibody
- CT-202: Nectin-4 x CD3 bispecific antibody
- Bispecific antibody platform designed for enhanced T cell activation
- Targets specific tumor-associated antigens to minimize off-target effects